查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1932058

動物模型平台市場（按動物類型、應用程式、最終用戶和服務類型分類）—全球預測，2026-2032年

Animal Model Platform Market by Animal Type, Application, End User, Service Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年動物模型平台市場價值為 5.9551 億美元，預計到 2026 年將成長至 6.4921 億美元，年複合成長率為 9.76%，到 ​​2032 年將達到 11.4313 億美元。

關鍵市場統計數據
基準年 2025 5.9551億美元
預計年份：2026年 6.4921億美元
預測年份 2032 11.4313億美元
複合年成長率 (%) 9.76%

將動物模型平台定位為轉化研究和治療開發中具有戰略意義、可重複且一體化的平台。

動物模型平台已從小眾的臨床前工具發展成為轉化研究和治療開發的重要策略支柱。研究人員和決策者現在期望的模型不僅能夠忠實地重現疾病生物學過程，還能整合分子測量、成像方法和數位表現型分析。因此，整個生態系統的優先事項正在轉向體內實驗的互通性、可重複性和倫理管治。

為了因應快速變化的科學、監管和商業性環境，我們需要更高的可重複性、更豐富的表現型分析和更完善的福利管治。

動物模型開發領域正經歷多重變革，這些變革共同重塑臨床前證據的生成、檢驗和應用方式。基因組編輯和精準育種技術的進步使得建構更生理相關性的模型成為可能，提高了機制研究的精確度，同時減少了對大型隊列的依賴。同時，數位病理學、高內涵成像和多組體學整合技術也為更深入的表現型分析和更豐富的轉化訊號提供了可能。

了解關稅主導的貿易趨勢如何重塑臨床前動物模型操作中的採購、供應彈性和策略採購。

諸如關稅調整之類的政策措施，即使不改變科學原理，也可能對動物模型平台產生不成比例的營運影響。對進口設備、特殊試劑或生物材料徵收關稅會延長採購前置作業時間、增加到岸成本，並迫使專案層級重新評估籌資策略。這些壓力往往會波及計劃進度，促使獎勵機構整合供應商、尋找國內替代方案或重新設計研究流程，以減少對易受影響的進口管道的依賴。

按物種、治療應用、最終用戶行為和服務類型區分動物模型的價值，以確定策略重點和權衡取捨。

細緻的細分框架闡明了不同動物模型交付服務在需求、能力和價值實現方面的差異。依物種分類，平台涵蓋非囓齒類和囓齒類物種，其中非囓齒類包括犬類、靈長類類和兔模型，而囓齒類則以小鼠和大鼠品系為主。每個物種都有不同的轉化優勢和操作考慮：非囓齒類動物在某些適應症方面往往具有更接近囓齒類動物的生理相似性，但同時也帶來了更大的倫理、物流和成本方面的複雜性；而囓齒類動物則具有基因操作性和高通量篩檢能力。

區域監管立場、創新叢集和供應鏈成熟度如何影響關鍵區域的籌資策略和試驗執行

區域趨勢正在影響整個動物模型生態系統的供應鏈、監管環境和客戶期望。在美洲，製藥和生物技術活動的集中推動了對綜合服務、快速反應和高標準數據可重複性的需求。該地區在先進表現型分析和轉化生物標記的應用方面也處於領先地位，這促使供應商提供經過嚴格檢驗的模型和端到端的研究執行方案。

透過整合的模型組合、先進的表現型分析、嚴格的品質系統和策略夥伴關係生態系統實現競爭優勢

競爭格局的特徵是服務供應商、供應商和機構研究中心的能力日益多元化。領先機構憑藉其專有的模型組合、先進的表現型分析平台和整合的資訊服務脫穎而出，這些服務能夠將體內訊號轉化為可執行的研發里程碑。其他機構則在人源化免疫系統、大型動物生理學和病原體特異性防護技術等專業領域競爭。

領導者可採取的切實可行的策略重點，以增強臨床前專案的可重複性、供應鏈韌性、福利管治和商業性誠信。

產業領導者必須採取積極主動的策略，在科學雄心與營運韌性之間取得平衡。首先，應優先投資於資料整合和標準化，將模型輸出轉化為可重複的、符合監管要求的證據。建立通用本體、統一的通訊協定以及生物材料的數位化可追溯性，以減少變異性並加快跨研究的比較。這項基礎設施也有助於提升與外部合作夥伴合作的價值。

採用透明、多維度的研究途徑，結合專家訪談、書面通訊協定和監管審查，確保研究結果的可靠性和有效性。

本分析的調查方法結合了多方面的證據基礎和系統性的文獻檢驗流程。主要定性資料是透過對科學家、專案主管、採購專業人員和服務供應商高階主管的深度訪談獲得的，旨在了解營運實務和策略重點。次要研究則整合了同儕審查文獻、監管指導文件和行業出版物，以闡明技術趨勢和倫理框架的背景。

整合科學嚴謹性、營運韌性和倫理透明度，以確保研究的可信度和專案的長期成功。

動物模型平台正處於關鍵的轉折點，科學進步、倫理期望和商業性壓力在此交匯融合。在此環境下，機構能否成功取決於其研究設計現代化、投資於可互通的數據系統以及採購是否符合動物福利和監管要求的能力。能夠應對這些關鍵挑戰的機構將能夠降低轉化風險、增強相關人員的信心，並加快臨床進展的決策週期。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依動物類型分類的動物模型平台市場

  • 不囓齒類動物
    • 狗
    • 靈長類動物
    • 兔子
  • 囓齒動物
    • 老鼠
    • 鼠

第9章 動物模型平台市場（依應用分類）

  • 循環系統
  • 糖尿病
  • 感染疾病
  • 神經科學
  • 腫瘤學

第10章 按最終用戶分類的動物模型平台市場

  • 學術研究機構
  • 合約研究機構
  • 政府機構
  • 製藥和生物技術公司

第11章：按服務類型分類的動物模型平台市場

  • 目錄模型
  • 客製化模型

第12章：按地區分類的動物模型平台市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按組別分類的動物模型平台市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國動物模型平台市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國動物模型平台市場

第16章：中國動物模型平台市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Champions Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Crown Bioscience Inc.
  • Cyagen Biosciences Inc.
  • Envigo
  • European Mouse Mutant Archive
  • genOway
  • Genoway SA
  • Horizon Discovery Group plc
  • Janvier Labs
  • MMRRC
  • MutantMouse Regional Resource Center
  • Ozgene Pty Ltd
  • PhenoSwitch Bioscience
  • PolyGene AG
  • PsychoGenics Inc.
  • Taconic Biosciences, Inc.
  • Texas A&M Institute for Genomic Medicine
  • The Jackson Laboratory
  • TransCure bioServices
Product Code: MRR-7B550E008F4E

The Animal Model Platform Market was valued at USD 595.51 million in 2025 and is projected to grow to USD 649.21 million in 2026, with a CAGR of 9.76%, reaching USD 1,143.13 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 595.51 million
Estimated Year [2026] USD 649.21 million
Forecast Year [2032] USD 1,143.13 million
CAGR (%) 9.76%

Positioning the animal model platform as a strategic, reproducible, and integrated foundation for translational research and therapeutic development

The animal model platform has evolved from a niche preclinical tool into a strategic pillar for translational research and therapeutic development. Researchers and decision-makers now expect models that not only reproduce disease biology with fidelity but also integrate with molecular readouts, imaging modalities, and digital phenotyping. As a result, priorities across the ecosystem have shifted toward interoperability, reproducibility, and ethical stewardship of in vivo work.

This evolution is driven by the convergence of technological advances in genetic engineering, imaging, and data analytics with heightened regulatory and ethical scrutiny. Translational value is judged not solely by internal validation but by how effectively a model de-risks downstream clinical programs and supports regulatory dialogue. Consequently, institutions and companies are rethinking portfolio composition, supplier relationships, and internal capabilities to ensure that animal models deliver actionable, reproducible insights that accelerate go/no-go decisions.

Looking ahead, the platform's strategic relevance will hinge on its ability to balance scientific rigor with operational scalability. Stakeholders must prioritize standardized protocols, transparent provenance of biological materials, and robust data capture that enables cross-study comparisons. These shifts will redefine partner selection criteria and internal resourcing, making the animal model platform a critical lever for both scientific innovation and program-level risk management.

Navigating rapid scientific, regulatory, and commercial shifts that demand higher reproducibility, richer phenotyping, and stronger welfare governance

The landscape for animal model development is undergoing several transformative shifts that collectively reshape how preclinical evidence is generated, validated, and applied. Advances in genome editing and precision breeding have enabled more physiologically relevant models, reducing reliance on large cohorts while enhancing mechanistic fidelity. Simultaneously, digital pathology, high-content imaging, and multi-omics integration have raised expectations for deep phenotyping and richer translational signals.

Concurrently, heightened regulatory scrutiny and public concern about animal welfare are accelerating adoption of standardized welfare metrics, alternatives where scientifically feasible, and more rigorous justification for in vivo studies. These ethical imperatives are prompting organizations to invest in training, oversight, and demonstrable compliance, which in turn affects procurement cycles and supplier selection. At the same time, commercial dynamics are shifting as contract research organizations expand capabilities to offer integrated services from model design through data analysis, blurring traditional vendor boundaries.

These shifts create both strategic opportunities and operational challenges. Organizations that proactively modernize study design, invest in cross-disciplinary data integration, and adopt transparent provenance and welfare practices will gain competitive advantage. Conversely, entities that fail to adapt risk longer lead times, higher costs, and weaker translational confidence. As a result, leaders must recalibrate investments in scientific capabilities, supply chain resilience, and governance to align with the new expectations of reproducibility, ethics, and data richness.

Understanding how tariff-driven trade dynamics can reshape procurement, supply resilience, and strategic sourcing across preclinical animal model operations

Policy actions such as tariff adjustments can have outsized operational consequences for animal model platforms even though they do not change scientific principles. Tariffs on imported equipment, specialized reagents, or live biological materials can lengthen procurement lead times, increase landed costs, and force program-level re-evaluations of sourcing strategies. These pressures often cascade into project timelines, creating incentives to consolidate suppliers, qualify domestic alternatives, or redesign study workflows to reduce dependence on fragile import channels.

From an operational perspective, increased import costs can lead to reprioritization of projects where in vivo work is most likely to yield high-value translational insights, while lower-priority studies may be delayed or shifted to alternative models. In parallel, service providers with global supply chains may experience margin compression and will likely pass some of the cost burden to customers or adjust their service portfolios. Moreover, the administrative overhead associated with customs compliance and tariff classification can lengthen contracting cycles and raise entry barriers for smaller research groups.

Strategically, tariffs can catalyze localization efforts and stimulate investment in domestic breeding, reagent production, and instrument manufacturing. Such reshoring can improve long-term supply resilience but requires near-term capital and capacity investments. For program leaders, the prudent response combines contingency planning, supplier diversification, and active dialogue with logistics, procurement, and legal teams to mitigate operational disruptions while preserving scientific rigor and timeline commitments.

Differentiating animal model value by species, therapeutic application, end-user behavior, and service modality to reveal strategic priorities and trade-offs

A nuanced segmentation framework clarifies how demand, capability, and value realization differ across animal model offerings. When differentiated by animal type, the platform encompasses both non-rodent and rodent species, with non-rodents including canine, primate, and rabbit models, and rodents dominated by mouse and rat strains. Each species class brings distinct translational advantages and operational considerations: non-rodents often provide closer physiological parallels for specific indications but carry higher ethical, logistical, and cost complexities, while rodents deliver genetic tractability and high-throughput screening capacity.

Examining use cases by application underscores divergent scientific needs. Cardiovascular and diabetes programs frequently require chronic study designs and physiologic endpoints, infectious disease work demands containment protocols and pathogen-specific expertise, neuroscience studies prioritize sophisticated behavioral and imaging readouts, and oncology projects focus on tumor biology, immune contexture, and combination therapy evaluation. These application-driven requirements influence model selection, study duration, and the depth of phenotyping required for regulatory engagement.

End-user segmentation further differentiates demand patterns and procurement behavior. Academic research institutes emphasize hypothesis-driven exploration and may prioritize flexible, low-cost catalog models, whereas contract research organizations deliver turnkey services and often invest in custom model creation to support sponsor studies. Government organizations can drive standards and large-scale initiatives, while pharmaceutical and biotech companies focus on de-risking clinical candidates and integrating preclinical outputs with development strategies.

Service type segmentation reveals a clear trade-off between accessibility and customization. Catalog models support rapid study starts with standardized provenance and reproducibility, while custom models enable bespoke genetic constructs, humanized systems, or disease-specific phenotypes that address unique program needs. Understanding how these segments interact is essential for designing offerings that align with scientific priorities, operational constraints, and end-user expectations.

How regional regulatory posture, innovation clusters, and supply chain maturation influence sourcing strategies and study execution across key geographies

Regional dynamics shape supply chains, regulatory posture, and customer expectations across the animal model ecosystem. In the Americas, a concentration of pharmaceutical and biotech activity drives demand for integrated services, rapid turnaround, and high standards for data reproducibility. This region often leads adoption of advanced phenotyping and translational biomarkers, creating pressure on suppliers to deliver tightly validated models and end-to-end study execution.

Across Europe, the Middle East & Africa, regulatory frameworks and public sentiment around animal welfare strongly influence study design and procurement decisions. Harmonization efforts and ethical oversight mechanisms in parts of Europe push institutions to adopt higher welfare standards and to document the 3Rs-replacement, reduction, and refinement-more rigorously. In regions of the Middle East and Africa, growth in research infrastructure and partnerships with multinational organizations is leading to selective capability expansion, particularly in centers of excellence and government-backed initiatives.

The Asia-Pacific region presents a heterogeneous landscape where innovation hubs coexist with rapidly expanding research capacity. Local manufacturing, reagent production, and specialized service providers are maturing, offering opportunities for nearshoring and cost optimization. At the same time, variability in regulatory expectations and infrastructure maturity means that program leaders must carefully align supplier qualifications and oversight practices when operating across multiple jurisdictions. Taken together, these regional differences affect strategic sourcing, timelines, and the types of partnerships that deliver the most value.

Competitive differentiation driven by integrated model portfolios, advanced phenotyping, rigorous quality systems, and strategic partnership ecosystems

The competitive environment is characterized by diversified capabilities across service providers, suppliers, and institutional research centers. Leading organizations differentiate through proprietary model portfolios, advanced phenotyping platforms, and integrated data services that convert in vivo signals into actionable development milestones. Others compete on specialized niches such as humanized immune systems, large animal physiology, or pathogen-specific containment expertise.

What distinguishes high-performing companies is their capacity to offer end-to-end solutions that encompass model design, ethical oversight, standardized protocols, and robust data management. This integrated approach reduces friction for sponsors, shortens study setup times, and enhances cross-study comparability. Strategic partnerships between technology vendors and service organizations are also creating bundled offerings that accelerate translational validation while keeping contractual complexity manageable.

At the operational level, companies are investing in quality systems, digital traceability for biological materials, and transparent provenance documentation to meet both client demands and regulatory expectations. Firms that prioritize workforce training, welfare standards, and cross-disciplinary collaboration tend to secure longer-term engagements and demonstrate higher client retention. In contrast, providers focused solely on price may win transactional business but face pressure when sponsors demand richer translational insight and stricter compliance.

Actionable strategic priorities for leaders to strengthen reproducibility, supply resilience, welfare governance, and commercial alignment in preclinical programs

Industry leaders must adopt a proactive strategy that balances scientific ambition with operational resilience. First, prioritize investments in data integration and standardization to convert model outputs into reproducible, regulatory-ready evidence. Establish common ontologies, harmonized protocols, and digital traceability for biological materials to reduce variability and accelerate cross-study comparisons. This foundational work will also improve the value of collaborations with external partners.

Second, diversify supplier networks and evaluate nearshoring options for critical inputs to mitigate trade disruptions and tariff exposure. Where appropriate, develop contingency plans with alternate vendors and maintain safety stock for mission-critical reagents and specialized equipment. Third, embed welfare and ethical governance into procurement and study design decisions; transparent welfare metrics and robust oversight strengthen public trust and simplify regulatory interactions.

Fourth, align commercial models to reflect the full value delivered by custom and integrated services, including options for outcome-linked contracting or bundled data services. Finally, invest in talent and cross-functional training so that study design, data science, and regulatory affairs work in concert from program inception. By taking these steps, organizations can enhance translational confidence, reduce operational risk, and extract greater strategic value from animal model platforms.

A transparent, triangulated research approach blending expert interviews, documented protocols, and regulatory review to ensure robust and defensible insights

The research methodology underpinning this analysis combined a multi-modal evidence base and a structured validation process. Primary qualitative inputs included in-depth interviews with scientists, program leaders, procurement specialists, and service provider executives to capture operational realities and strategic priorities. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, and industry publications to contextualize technological trajectories and ethical frameworks.

The analytical approach emphasized triangulation: findings from interviews were cross-checked against documented protocols, supplier capabilities, and public statements to ensure consistency and reduce bias. Case studies were used to illustrate practical implications of sourcing decisions, model selection, and welfare governance. Throughout the process, attention was paid to provenance of materials and documented reproducibility measures to assess the robustness of supplier claims.

Limitations were transparently acknowledged and addressed through targeted follow-up interviews and sensitivity checks. Where gaps existed in publicly available data, the methodology relied on validated expert opinion and documented operational practices rather than extrapolation. This approach ensured that conclusions are grounded in observable trends and operational realities, providing a defensible basis for the recommendations and insights offered herein.

Integrating scientific rigor, operational resilience, and ethical transparency to secure translational confidence and long-term program success

The animal model platform stands at an inflection point where scientific advances, ethical expectations, and commercial pressures converge. Success in this environment will depend on an organization's ability to modernize study design, invest in interoperable data systems, and align procurement with welfare and regulatory requirements. Entities that embrace these imperatives will reduce translational risk, improve stakeholder confidence, and accelerate decision cycles for clinical advancement.

Operational resilience will be equally important: diversified sourcing, strategic nearshoring where appropriate, and clear contingency plans can mitigate the impact of trade disruptions or supply shortages. At the same time, sustained investment in workforce capability, welfare oversight, and documentation of reproducibility will form the foundation for long-term partnerships with sponsors and regulators alike. Ultimately, the institutions that integrate scientific rigor with operational foresight and ethical transparency will be best positioned to translate preclinical findings into clinical and commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Model Platform Market, by Animal Type

  • 8.1. Non-Rodent
    • 8.1.1. Canine
    • 8.1.2. Primate
    • 8.1.3. Rabbit
  • 8.2. Rodent
    • 8.2.1. Mouse
    • 8.2.2. Rat

9. Animal Model Platform Market, by Application

  • 9.1. Cardiovascular
  • 9.2. Diabetes
  • 9.3. Infectious Disease
  • 9.4. Neuroscience
  • 9.5. Oncology

10. Animal Model Platform Market, by End User

  • 10.1. Academic Research Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Government Organizations
  • 10.4. Pharmaceutical Biotech Companies

11. Animal Model Platform Market, by Service Type

  • 11.1. Catalog Models
  • 11.2. Custom Models

12. Animal Model Platform Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Animal Model Platform Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Animal Model Platform Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Animal Model Platform Market

16. China Animal Model Platform Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Champions Oncology, Inc.
  • 17.6. Charles River Laboratories International, Inc.
  • 17.7. Crown Bioscience Inc.
  • 17.8. Cyagen Biosciences Inc.
  • 17.9. Envigo
  • 17.10. European Mouse Mutant Archive
  • 17.11. genOway
  • 17.12. Genoway S.A.
  • 17.13. Horizon Discovery Group plc
  • 17.14. Janvier Labs
  • 17.15. MMRRC
  • 17.16. MutantMouse Regional Resource Center
  • 17.17. Ozgene Pty Ltd
  • 17.18. PhenoSwitch Bioscience
  • 17.19. PolyGene AG
  • 17.20. PsychoGenics Inc.
  • 17.21. Taconic Biosciences, Inc.
  • 17.22. Texas A&M Institute for Genomic Medicine
  • 17.23. The Jackson Laboratory
  • 17.24. TransCure bioServices

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL MODEL PLATFORM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL MODEL PLATFORM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANIMAL MODEL PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANIMAL MODEL PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY CANINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY CANINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY CANINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY PRIMATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY PRIMATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY PRIMATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY RABBIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY RABBIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY RABBIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY MOUSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY MOUSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY MOUSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY RAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY RAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY RAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY NEUROSCIENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY NEUROSCIENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY NEUROSCIENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY GOVERNMENT ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY GOVERNMENT ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY GOVERNMENT ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY CATALOG MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY CATALOG MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY CATALOG MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY CUSTOM MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY CUSTOM MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY CUSTOM MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS ANIMAL MODEL PLATFORM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ANIMAL MODEL PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ANIMAL MODEL PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL PLATFORM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ANIMAL MODEL PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST ANIMAL MODEL PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA ANIMAL MODEL PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ANIMAL MODEL PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN ANIMAL MODEL PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GCC ANIMAL MODEL PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 130. GCC ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 131. GCC ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. GCC ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION ANIMAL MODEL PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS ANIMAL MODEL PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. G7 ANIMAL MODEL PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 151. G7 ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 152. G7 ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. G7 ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NATO ANIMAL MODEL PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 158. NATO ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 159. NATO ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. NATO ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ANIMAL MODEL PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES ANIMAL MODEL PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA ANIMAL MODEL PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA ANIMAL MODEL PLATFORM MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA ANIMAL MODEL PLATFORM MARKET SIZE, BY NON-RODENT, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA ANIMAL MODEL PLATFORM MARKET SIZE, BY RODENT, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA ANIMAL MODEL PLATFORM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA ANIMAL MODEL PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA ANIMAL MODEL PLATFORM MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)